IP6K3 (inositol hexakisphosphate kinase 3) is an enzyme that converts inositol hexakisphosphate (IP6) to inositol pyrophosphates, specifically 5-diphosphoinositol pentakisphosphate (IP7), which function as high-energy signaling molecules 1. The enzyme is highly expressed in skeletal muscle and myotubes, with expression elevated under metabolic stress conditions including diabetes, fasting, and muscle disuse 1. Mechanistically, IP6K3 operates through both enzymatic activity in synthesizing inositol pyrophosphates and non-enzymatic protein-protein interactions, including association with dynein intermediate chain 2 (DIC2) at the leading edge of migrating cells to promote focal adhesion turnover 2. IP6K3 plays critical roles in metabolic regulation, as IP6K3 knockout mice display improved glucose tolerance, reduced blood glucose and insulin levels, decreased fat mass, and notably extended lifespan with reduced S6 ribosomal protein phosphorylation 1. Disease relevance includes associations with late-onset Alzheimer's disease, where specific promoter polymorphisms affect disease susceptibility, and ankylosing spondylitis in HLA-B27 positive individuals 34. Clinically, IP6K3 variants show complex relationships with both neurodegeneration risk and longevity, suggesting it functions at the crossroads of cellular survival and pathological processes 5.